Cerevance to Participate in the TD Cowen Treatment Advancements in Obesity and Related Disorders SummitBOSTON, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment of neurodegenerative diseases and obesity, today announced participation in a panel discussion at the TD Cowen Treatment Advancements in Obesity and Related Disorders Summit taking place virtually on November 24, 2025.
Cerevance to Present Phase 2 Data on Solengepras in Parkinson’s Disease at the 2025 International Congress of Parkinson's Disease and Movement DisordersBOSTON, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Cerevance, a clinical-stage biopharmaceutical company advancing targeted therapies for neurodegenerative diseases and obesity, today announced an upcoming oral presentation at the 2025 MDS International Congress of Parkinson's Disease and Movement Disorders being held from October 5-9 in Honolulu.
Cerevance to Participate in Piper Sandler Virtual CNS SymposiumBOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment of neurodegenerative diseases and obesity, today announced participation at the Piper Sandler Virtual CNS Symposium being held from August 14-15, 2025.
Cerevance Announces Presentations at the Alzheimer's Association International Conference 2025BOSTON, July 11, 2025 (GLOBE NEWSWIRE) -- Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment of neurodegenerative diseases and obesity, today announced upcoming presentations at the Alzheimer's Association International Conference (AAIC) 2025 being held in Toronto from July 27-31, 2025.
Cerevance Presents Positive Results from Phase 1 Study of CVN293 at American Academy of Neurology 2025 Annual MeetingBOSTON, April 08, 2025 (GLOBE NEWSWIRE) -- Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment of neurodegenerative, psychiatric, and central nervous system-controlled metabolic disorders, today announced results from its Phase 1 trial of CVN293, a novel KCNK13 inhibitor targeting neuroinflammation. The data showed that CVN293 was generally well-tolerated in healthy adults following single and 14-day multiple dosing and showed evidence of robust brain penetration. The data was presented today in a poster session at the American Academy of Neurology (AAN) 2025 Annual Meeting in San Diego.
Cerevance Presents Topline Results from Phase 2 ASCEND Trial of Solengepras as Monotherapy Treatment for Early-Stage Parkinson’s Disease at AD/PD 2025BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment of neurodegenerative, psychiatric, and central nervous system-controlled metabolic disorders, today announced topline results from the Phase 2 ASCEND trial of solengepras as an investigational monotherapy in patients with early, untreated Parkinson’s disease. The data was presented today in the “Advances in PD” Symposium session at AD/PD™ 2025, the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders, in Vienna.
New Data to Be Presented at Upcoming Congresses Showcase Cerevance's Advanced Clinical Program in Parkinson’s Disease and Deep Pipeline for CNS-based DisordersBOSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment of neurodegenerative, psychiatric, and central nervous system-controlled metabolic disorders, today announced upcoming presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD™ 2025) being held April 1-5 in Vienna, and the American Academy of Neurology (AAN) Annual Meeting being held April 5-9 in San Diego.
